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Abstract
Despite an enormous research effort, most cases of late-onset Alzheimer’s disease (LOAD) still remain unexplained and the
current biomedical science is still a long way from the ultimate goal of revealing clear risk factors that can help in the
diagnosis, prevention and treatment of the disease. Current theories about the development of LOAD hinge on the premise
that Alzheimer’s arises mainly from heritable causes. Yet, the complex, non-Mendelian disease etiology suggests that an
epigenetic component could be involved. Using MALDI-TOF mass spectrometry in post-mortem brain samples and
lymphocytes, we have performed an analysis of DNA methylation across 12 potential Alzheimer’s susceptibility loci. In the
LOAD brain samples we identified a notably age-specific epigenetic drift, supporting a potential role of epigenetic effects in
the development of the disease. Additionally, we found that some genes that participate in amyloid-b processing (PSEN1,
APOE) and methylation homeostasis (MTHFR, DNMT1) show a significant interindividual epigenetic variability, which may
contribute to LOAD predisposition. The APOE gene was found to be of bimodal structure, with a hypomethylated CpG-poor
promoter and a fully methylated 39-CpG-island, that contains the sequences for the e4-haplotype, which is the only
undisputed genetic risk factor for LOAD. Aberrant epigenetic control in this CpG-island may contribute to LOAD pathology.
We propose that epigenetic drift is likely to be a substantial mechanism predisposing individuals to LOAD and contributing
to the course of disease.
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Introduction
Alzheimer’s disease (AD) is the most prominent form of
dementia among the elderly. Despite enormous research efforts,
the etiology of AD remains obscure and puzzling. Although some
genes for some early-onset familial forms of Alzheimer’s disease
have been identified (,5% of cases), the overwhelming proportion
of diagnosed AD cases remains unexplained. These circumstances
led to a rethinking of the classical molecular approaches, shifting
the emphasis from genetic causative factors to epigenetic and
environmental effects. Yet, empirical support for specific environ-
mental risk has been very inconsistent [1]. Genetic influences seem
to play a more significant role in the onset of the rare early-onset
form of AD (EOAD) [2]. In these cases mutations in the amyloid-b
precursor protein (APP), and the presenilin genes PSEN1 and
PSEN2 are known to be associated with autosomal dominant
EOAD. A different picture seems to emerge for late-onset AD
(LOAD), a common sporadic form of the illness affecting
individuals above the age of 65 years. In contrast to monogenic
diseases, LOAD exhibits numerous non-Mendelian anomalies that
suggest an epigenetic component in disease etiology. Such
anomalies include among others: 1.) Sporadic cases dominate
over familial ones; 2.) estimated concordance rates for monozy-
gotic twins are significantly below 100%, a hallmark of complex
non-Mendelian diseases; 3.) differential susceptibility and course of
illness in males and females [3,4]; 4.) parent-of-origin effects [5];
5.) late age of onset; 6.) brain chromatin abnormalities, including
aberrant histone modifications; 7.) non-Mendelian inheritance
pattern; 8.) abnormal levels of folate and homocysteine, indicative
of an abnormal methylation homeostasis in the brain of AD
patients; 9.) a disturbed control of the epigenetically regulated
circadian clock and 10.) monoallelic expression patterns of
susceptibility genes [6]. Compared to genetic causes, epigenetic
factors are probably much more suited to explain the observed
anomalies in LOAD as aberrant epigenetic patterns may be
acquired during many developmental stages. The epigenome is
particularly susceptible to deregulation during early embryonal
and neonatal development, puberty and especially old age [7],
which is the most important known risk factor for AD.
Surprisingly, little is known about the role of an epigenetic
componentinthe developmentofAD.Onestudyfromthe early90’s
on one post-mortem brain sample of an unaffected patient suggested
that the APP promoter is always unmethylated in brain and hence
may not be controlled by DNA methylation in the brain of healthy
individuals [8]. However, this study did not compare statistical
amounts of samples; neither did the study reveal whether DNA
methylation of the interrogated sites is present in AD patients.
AnotherstudybySchwobetal.foundnosignificantdifferenceintotal
percent methylation of CCGG sites from brain DNA of AD patients
compared with 20 normal subjects [9]. However, this method did
not possess the sensitivity to distinguish between different DNA
methylation profiles, genomic distribution of methylcytosine nor if
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cells. It isnowacknowledged that itis importanttoknow moreabout
the epigenetic patterns of the genes involved in AD pathogenesis to
understand the mechanisms that regulate gene function and to
potentially enable pharmacological intervention on the epigenetic
level.
In this study we asked whether DNA methylation patterns in post-
mortem brains and lymphocytes from LOAD patients are different
from patterns found in healthy individuals and if age affects the
distribution of these profiles. Hence, we performed a hypothesis-
driven analysis of DNA methylation patterns across candidate genes
for which ap r i o r ievidence for a role in the etiology of AD exists.
Additionally, we analysed the promoter methylation of genes which
are essential components of the epigenetic machinery and thus may
serveasindicatorsofglobalepigeneticmalfunctionsinLOAD.Here,
we demonstrate that LOAD patients have a larger epigenetic
distance from the norm in brain tissue compared with controls and
that the epigenetic distance increases with age, supporting a role of
epigenetic effects in the development of the disease. Some genes that
play central roles in amyloid-b processing (i.e. PSEN1 and APOE)
and methylation homeostasis (i.e. MTHFR and DNMT1) also show
a significant interindividual epigenetic variability, which may
contribute to AD predisposition.
Results
DNA Methylation analysis was performed using base-specific
cleavage of single-stranded nucleic acids with MALDI-TOF mass
spectrometry analysis of the cleavage products [10,11] (for details
see supplementary Material & Methods S1). All measurements
were highly reproducible and 123 of the 124 CpG units analyzed
in this study yielded successful measurements in .98% of samples.
Of the total 5796 interrogated CpG units in the 46 individuals,
only 59 units (,1%) could not be analyzed.
Overall DNA methylation
From the 12 analyzed CpG-rich regions, 9 were mostly
unmethylated (,20% methylation), 2 gene promoters were partly
methylated (20–50%) and only one hypermethylated (.50%
methylation). This result is in agreement with earlier observation
of CpG island methylation patterns on chromosome 6, 20 and 22,
where the majority of CpG islands (CGIs) were unmethylated and
only a small fraction (9.2%) were hypermethylated [12]. The
hypermethylated CGI was the only region analyzed outside of a
promoter region.Suchhypermethylated loci are generally associated
with a closed chromatin structure [13], whereas the analyzed 59-
promoter regions might reflect an open chromatin structure. Most
genes such as APP, NCSTN, BACE, SIN3A, APH1B, HTATIP or
DNMT1 revealed the same methylation patterns in the majority of
brain tissues and in the lymphocytes (Fig. 1). Although some
interesting age- and gene-specific trends could be observed, no
significant changesinoverallmethylation patternscould be observed
in AD patients compared to the controls (data not shown).
Neither brain samples nor lymphocytes exhibited significant
overall methylation difference between the sexes. Similarly, no
significant tissue-specific differences in methylation levels could be
observed. Generally, it is assumed that tissue-specific transcription
is controlled by tissue-specific differentially methylated regions (T-
DMRs). Such regulatory elements are essential for specifying tissue
type identity in mammals. Hierarchical clustering of our data
showed that biological replicates of both tissue types did not cluster
together (data not shown), indicating a lack of tissue-specific
methylation profiles in the analyzed genes. This result is not
surprising, since none of the analyzed genes are believed to have a
role in tissue differentiation mechanisms and because only a small
fraction of the loci in the human genome are differentially
methylated in different tissues [12,14]. Furthermore, according to
online expression databases, most of the analyzed genes are
abundantly expressed in multiple tissues including brain and
blood. Only 5 genes (APOE, TFAM, APP, APH1B and DNMT1)
demonstrate major expression differences in the studied tissues;
however, the influence of DNA methylation on their promoter is
poorly studied. For APP, the relationship between promoter
methylation and gene expression has been explored. It was found
that the promoter region in humans and primates displayed tissue-
and brain-region-specific profiles of methylation, which crudely
reflect APP expression patterns [15]. Similarly, a direct relation-
ship between methylation level and promoter activity are known
for PSEN1 and BACE [16]. Both genes are expressed at high
levels in brain cells as well as in lymphocytes and are, as expected,
unmethylated in both tissues.
Of all the genes analysed, only within the gene for apolipopro-
tein E (APOE) a hypermethylated CGI could be identified (see
Fig. 2a). Interestingly, the APOE gene belongs to a group of genes
that do not possess a classical CpG island in their promoters, but
rather a low-CpG density region [17]. However, the gene contains
a high-density CGI at its 39end that covers exon 4, which contains
the sequences for the major haplotypes (e2–e4), which determine
risk to develop AD. APOE is the prime candidate for late-onset
Alzheimer’s disease and patients are routinely screened for these
APOE genotypes. It is not known if the internal CGI possesses a
regulatory function, however brain specific transcripts originating
directly downstream of this CGI (i.e. AJ249921) were previously
identified. DNA methylation patterns within the 39-CGI were
close to 100% in all individuals, with the exception of one LOAD
patient who had a methylation of below 80% averaged over the 10
CpG sites analysed. In total, the interindividual variation within
the 39-CGI was very low (see Fig. 2b). The opposite pattern could
be observed for the GC-poor 59-promoter, which was hypomethy-
lated in all individuals, however with a much higher degree of
interindividual variance. The methylation increased downstream
of the core promoter, which spans from about 500 bp 59 to the
transcription start site up to 300 bp in intron 1. The impact of
DNA methylation on APOE promoter activity itself is unknown
since the regulation of APOE is highly complex and does not only
rely on the 59-promoter, it also requires an interaction of proximal
and distal regulatory regions with transcription factors to impart a
net effect on APOE expression. In human brain, most of the cis-
acting variance in APOE expression is accounted for by the e4
haplotype, but there are additional, small, cis-acting influences
associated with promoter genotypes [18]. The e4 sequence (that is
usually associated with a higher risk of LOAD) may change the
epigenetic function of the methylated 39-CGI since the e4 allele
introduces a C R T transition that is associated with a loss of a
methylatable CpG unit (Fig. 2c). The risk associated with the e4
allele is dose dependent and it was shown previously that the
relative APOE e4 mRNA level is increased in AD compared to
controls, suggesting that variability in the neuronal expression of
APOE contributes to disease risk [19,20].
Epigenetic distance
To test if there is a significant epigenetic difference between the
healthy control group and LOAD patients and to characterize
individuals depending on their epigenetic profile, we analyzed the
epigenetic distance of each individual to the norm (the median
methylation of the healthy control individuals). The epigenetic
distance was represented either as the Euclidean distance of the
profile of an individual compared to the group of unaffected
Alzheimer’s Epigenetics
PLoS ONE | www.plosone.org 2 July 2008 | Volume 3 | Issue 7 | e2698Figure 1. DNA methylation profiles of GC-rich regions in potential AD-susceptibility genes. A: Genes involved in LOAD or genes that are
a central part of the epigenetic machinery of the cell. A strong interindividual variance in DNA methylation could be observed within the promoters
of MTHFR, DNMT1 for cases and controls and in TFAM for LOAD patients. Note that all ‘abnormal’ patterns within HTATIP, NCSTN, TFAM or SIN3A are
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difference between an individual and the norm at a site (Fig. 3),
since any epigenetic deregulation can involve demethylation as
well as de novo methylation. Interestingly, for all analysed genes
we found that the methylation patterns in brains of LOAD cases
were slightly more dissimilar to the norm compared with control
brains (Fig. 3a). Some individuals, as exemplified with LOAD
patient #13, displayed a significant epigenetic distance. In total, 9
out of the 10 most ‘abnormal’ methylation patterns were observed
in LOAD patients and only one in a control brain sample (control
#29; Fig. 3b). Of all the genes, the gene for mitochondrial
transcription factor A (TFAM), a key activator of mitochondrial
transcription in mammals, displayed the strongest epigenetic
distance in LOAD brains. In total, 16 out of 24 LOAD patients
(67%) displayed a notable epigenetic distance from the norm in
TFAM, whereas only one of the controls did.
Figure 3d exemplifies a typical methylation pattern of one LOAD
brain sample from a 94 year old female patient (AD #11), that
displays a relative large epigenetic distance from the norm in the
putative LOAD susceptibility genes PSEN1, APOE and TFAM as
well as in DNMT1 and MTHFR. Similar patterns were observed in
several individuals, reflected in the fact that the genes deregulated in
the aged brain of individual #11 are the most variant genes in all
individuals. In general, most genes displayed a very low interindivid-
ual variance in all analysed individuals, however, four CpG islands
displayed a moderate to large interindividual variance, especially the
promoters of DNMT1, MTHFR, APOE and largest in PSEN1
(Fig. 3e). The most variable single CpG sites were observed for
DNMT1 CpG’s #2a n d#15 and MTHFR CpG’s #5a n d#7. No
significant tissue- or gender-specific variance could be identified.
Age dependent epigenetic drift
By calculating the Euclidean distance to the norm for each
methylation profile, we found a notable epigenetic drift from the
norm in the brains of the LOAD patients but not in controls (see
Fig. 4a). According to the theory of epigenetic drift (see discussion),
AD patients may undergo an enhanced epigenetic drift or
alternatively their epigenomes were already at an advanced level
of abnormality earlier in life, for example due to the influence of
environmental factors, transgenerational effects or by disruption of
the epigenetic machinery. A sign of potential deregulation of the
epigenomic machinery in the brains of affected individuals may be
the observation that aberrant DNA methylation patterns are not
uniform and occur either as demethylation or as de novo
methylation. Indeed, for the majority of the analyzed CpG
islands, we could not observe a directed methylation change
Figure 2. DNA methylation and epigenetic variance in the APOE gene. A: DNA methylation increases from the upstream core promoter
gradually towards intron 1. The first exon is non-coding, exon 2 codes for the signal peptide and exons 3 and 4 for the mature protein. The internal
39-CGI, covering exon 4, displays hypermethylation in all individuals. The 39-CGI contains the sequences for the e2, e3 and e4 haplotypes. The e4
haplotype of APOE is the only undisputed genetic risk factor for late-onset Alzheimer’s disease. Interindividual variance of DNA methylation was
notably in the APOE promoter but not in the 39-CGI. B: The occurrence of an e2o re4 haplotype removes a CpG dinucleotides from the 39-CpG island
potentially affecting the higher order chromatin structure, that could result in aberrant regulation of APOE and the downstream transcript AJ249921.
C=Controls, AD=Alzheimer patients; Ly=Lymphocytes, Br=brain.
doi:10.1371/journal.pone.0002698.g002
from LOAD cases and exclusively observed in brain tissue. B: Methylation profiles of the promoter region of the APP gene and genes involved in APP
processing. PSEN1 demonstrated the highest interindividual variation of all genes analyzed, whereas BACE, APP and APH1B did not display any
significant variation in the analyzed individuals.
doi:10.1371/journal.pone.0002698.g001
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of the genes displayed a bivalent distribution of methylcytosine
with age, characterized by a trend towards a progressive
demethylation with age in normal control brains, whereas the
LOAD brains displayed the opposite pattern with an increase in
DNA methylation in these CGIs. The opposite pattern was
strongest for MTHFR and APOE. This result is especially
interesting for the APOE promoter, since APOE is the main
Figure 3. DNA methylation difference from the norm in brain. A: The AD cases show the largest epigenetic distance, measured as the
average absolute methylation difference from the norm in all genes. B: The 10 individuals with the biggest epigenetic difference to the norm. Only
one control individual (#29) displayed a notably epigenetic distance from the norm, whereas all other individuals with notable epigenetic distances
are LOAD cases. C: DNA methylation differences in the TFAM gene between AD cases and controls. D: Example of an AD case (#11) with large
epigenetic distance to the norm. The brain DNA of this 94 year old female shows a hypomethylation of PSEN1, whereas the APOE promoter, DNMT1,
MTHFR and TFAM are hypermethylated compared to the norm. E: Interindividual variation of DNA methylation levels in brain and lymphocytes of
LOAD patients and controls. The largest interindividual variance was observed for the promoters of PSEN1 and APOE, which are the prime candidates
for LOAD susceptibility.
doi:10.1371/journal.pone.0002698.g003
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MTHFR and APOE in individuals 30 years of age apart
decreased in the control brains by 10.6%, whereas the AD
patients methylation level increased by 6.8% (see Supporting Fig.
S2). Although some of the genes behaved similar in lymphocytes,
the overall trend was different and could not be reproduced in
lymphocytes. Similarly, no gender-specific methylation changes
with age could be identified (see Supporting Table S2).
Epigenetic disease signatures
To identify disease specific epigenetic signatures or classifiers
that can be used as markers to characterize or prognosticate
LOAD we performed a detailed statistical investigation including
Wilcox rank sum test, hierarchical clustering and discriminant
analysis of all the analysed CpG sites (see Material and Methods).
We found that only a small subset of the CpG sites included in the
study were significantly different in the LOAD patients brains
compared to control brains (Fig. 5a). The most significant
differences were found in the APOE and TFAM promoters
(TFAM CpG #1, #6 and #14; APOE CpG #1 and #2),
however, these signatures were associated with only small changes
in methylation levels (,10%). Other loci, especially a group of
several CpG sites within the PSEN1 promoter were associated
with stronger methylation differences, however, only in a subset of
individuals, which is reflected in the fact that PSEN1 is the most
variable of the analysed genes (Figs. 3e and 5a).
It is interesting to note that the changes observed in LOAD
patients were usually correlated with a further demethylation of the
PSEN1 and TFAM promoters. The analysis of differentially
methylated CpG sites in lymphocytes could not reproduce the
patterns that we found in the brain samples (Fig. 5b), and also did not
reveal clusters of affected CpG sites, but merely single disease specific
markers; which may indicate that no specific gene promoters are
altered in the blood of LOAD patients. Hence, for the analysed genes,
the use of specific blood biomarkers for the diagnostics of LOAD
seem unlikely, although these sites can be used to classify the majority
of our LOAD cases and controls with high accuracy (Fig. 5c).
Sites for optimalperformance ofclassifier-setsweredeterminedby
the technique of receiver-operating-characteristic (ROC) curve.
Points in an ROC plot indicate the sensitivities and specificities of a
given group of methylation classifiers. In general, true positiveclaims
on the LOAD brains increase at the cost of increasing false positive
claimson thecontrol brains.Forthe brainsamples,a combination of
several markers was able to classify over 80% of the brain samples
correctly as LOAD. Using blood markers, the classification could
reach over 90%. However, it is not known if the same classifiers can
be successfully applied to other LOAD cases.
Disease classification was complemented with clustering algo-
rithms that may reveal systemic changes in the brains of LOAD
patients and that serve as training sets for the potential biomarkers.
Clustering of the 34 brains was done by applying a divisive
hierarchical clustering algorithm using the top five methylation
sites (see Material and Methods). The resulting tree shows that the
5 most significant CpG sites serve well as biomarkers for
discrimination, with a clustering of the majority of LOAD samples
(Fig. 5d). These data show that epigenetic markers may be suitable
to further characterize LOAD and other complex diseases;
however more detailed analyses, including a whole genome
approach with many samples, are needed.
Discussion
It is increasingly acknowledged that epigenetic phenomena may
be a crucial component in the development of complex brain
disorders. Indeed, we and colleagues recently demonstrated that
Figure 4. Age-dependent epigenetic drift in brain samples. A: The epigenetic Euclidean distance of LOAD patients compared to the
‘epigenetic norm’ increases with age (Pearson product-moment correlation coefficient=0.41, p=0.045), whereas no significant drift could be
identified for the control individuals. Circles=LOAD cases, Boxes=controls. B: Correlation between epigenetic drift and age of single CpG sites in
LOAD post-mortem brain samples (Spearman correlation). Several of the sites display a significant age-dependent drift in the LOAD patients; most
notably in the NCSTN and DNMT1 promoter sequences.
doi:10.1371/journal.pone.0002698.g004
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diseases such as schizophrenia and bipolar disorder [21].
Surprisingly, although many non-Mendelian characteristics point
also to an involvement of epigenetic factors in age-related diseases,
very little is known about epigenetic patterns in AD and other
neurodegenerative disorders. From twin studies we know that the
onset of AD in identical twins not only can differ by more than
20 years [22,23], we also know that young identical twin pairs are
essentially indistinguishable in their epigenetic profiles, whereas
older twin pairs show substantial differences in their epigenetic
marks [24,25]. These variations can be explained by an epigenetic
drift caused by one’s environmental exposure, lifestyle, diet, drug
abuse, or merely stochastic fluctuations. Conventional wisdom is
that the majority of environmental effects are likely to have only a
Figure 5. DNA methylation difference between AD cases and controls. A, B: Volcano plots of methylation differences by single CpG sites in
brain and lymphocytes. Methylation differences are calculated by the median of LOAD methylation minus the median of the controls. P-values were
calculated by two-sample Wilcoxon tests. The strongest disease-specific epigenetic effect in the LOAD brains could be observed for PSEN1; however,
low p-values for that gene indicate high interindividual variance. C: Receiver operating characteristic (ROC) curve of several CpG-site combinations,
which may be used for disease classification. The ROC curve represents the fraction of true positives (TPR=true positive rate) vs. the fraction of false
positives (FPR=false positive rate). TPR claims on the 24 AD brains increase at the cost of FPR claims on the control brains. The ideal scenario is to
have a high TPR combined with a low FPR. The diagonal line divides the ROC space in areas of good or bad classification/diagnostic. Points above the
diagonal line indicate good classifiers, while points below the line indicate poor ones. Best accuracy brain=0.85; lymphocytes=0.92. D: Hierarchical
clustering of LOAD patients and controls using the five top brain methylation biomarkers reveals a clustering of a large group of the LOAD samples
(see also Supporting Fig. S3).
doi:10.1371/journal.pone.0002698.g005
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that age-specific effects would cause only minor epigenetic changes
in a subset of genes. Indeed, we did not find major ‘all or nothing’
DNA methylation changes in the brains of LOAD patients.
Nevertheless, the observed methylation drift and the fact that the
most unusual methylation patterns were almost always observed in
the LOAD brains support the role of epigenetic deregulation in age-
dependent AD. Most of the analyzed CGI regions were predom-
inantly unmethylated and it seems plausible that even small changes
in the methylation levels of the CGI’s interfere with critical gene
regulatory functions, potentially accumulating to finally cause the
disease. A subset of the analyzed gene promoters (i.e. NCSTN,
TFAM, SIN3A or HTATIP) displayed only one or two ‘abnormal’
methylation patterns observed only in the LOAD brains. Yet, since
each cell type in the brain possesses a characteristic profile of DNA
methylation specific to its function, we cannot rule out that the
observed methylation patterns could also be the consequence of a
shift in cellular population heterogeneity, associated with loss of
specific cell types in the diseased individuals. Shifts in cell
heterogeneity were described as ‘one of the major stumbling blocks
of biological investigations of aging’ [25]. To address this limitation,
future studies on epigenetic drift in the aging brain will require
special methodologies such as laser capture microdissection (LCM)
and flow cytometry combined with whole-genome single-cell
methylome profiling. Nevertheless, the occurrence of abnormal
methylation pathways inthe brain that precede pathological findings
and dementia supports our model that epigenetic drift may be one
contributor to LOAD predisposition [26–29].
Interindividual variance
In our study, the largest interindividual variance in DNA
methylation was observed in the PSEN1 and APOE promoters,
the two genes that are genetically associated with LOAD. In the case
of PSEN1, it is known that its promoter is regulated by DNA
methylation [16] and may be up- or down-regulated in AD,
depending on the cell-type analyzed [30]. In the analyzed LOAD
brain samples, abnormal PSEN1 methylation patterns were usually
associated with hypomethylation of the promoter. This finding may
be important, because hypomethylation could induce an over-
expression of PSEN1, which could result in an imbalance in b-
amyloid production [31]. Previously, we and colleagues showed that
PSEN1 as well as PSEN2 contain epigenetic variability already in
male germ cells [32]. Such patterns may be transmitted directly
through the germline ormaybere-established postzygotically,which
may contribute to different susceptibility to disease later in life.
Bimodal methylation patterns in APOE
We found the APOE promoter region to be one of the most
variably methylated sequences. APOE is the major susceptibility
gene for late-onset AD in the human genome [33]. Nevertheless,
although there are links between APOE genotype (i.e. the APOE
e4 allele) and SNP rs4420638, located 14 kbp distal to APOE, it
seems that APOE genotyping has no major role in predicting the
risk of developing AD. Even individuals with the rare e4/e4
genotype have, on average, a greater than 50% chance of escaping
the disease [2], indicating that genetic variants of this allele are not
a sufficient cause of AD. Interestingly, as shown in Fig. 2c,
although the APOE allele’s e2 and e4 also change the amino acid
sequence of APOE, they also alter the epigenetic information of
the methylated downstream CGI, by removal of a CpG
dinucleotide. Elimination of one of these methylated CpG units
thus may impair the regulatory function of the 39-CGI. Indeed,
the presence of the e2o re4 alleles alone is sufficient to affect the
expression patterns of APOE [18]. An even stronger effect on the
transcription level of the gene is exerted by the main promoter,
which contains numerous cis-acting positive and negative regula-
tory elements [34], although the CpG density of the APOE
promoter is comparably low.
Epigenetic drift and age-effects
For all of the analyzed CGI’s, the absolute epigenetic difference
from the healthy norm was higher in LOAD brains compared to
the controls. Although these changes were only small, they may
indicate a genome wide epigenetic drift in LOAD brains that is
accompanied by a slighter increased variance with age in the
LOAD brains but not in the controls. It is important to note that it
is unlikely that age-dependent epigenetic drift will manifest itself by
switching AD susceptibility genes completely on or off, especially if
the majority of changes are due to stochastic fluctuations, which
could be more common than is generally assumed [35]. In contrast
to single nucleotide polymorphisms (SNPs), epigenetic modifica-
tions may exert only subtle effects on the regulation of specific
genes. Thus, abnormal DNA methylation may only cause a
disease phenotype when several loci are affected at the same time,
reflected as epigenetic distance to the norm, or by increasing the
predisposition to AD of affected individuals, which are already
prone to develop AD by other predisposing factors such as APOE
genotype or SNPs (2-hit hypothesis). We observed the strongest
epigenetic distance in patient brains for the TFAM promoter.
Mutations in TFAM, which is required for mitochondrial DNA
copy number regulation and maintenance, may be a moderate risk
factor in sporadic AD. Although the disease specific pattern
methylation markers within TFAM may help characterizing the
disease (Fig. 3c), the measured profiles within TFAM alone are not
powerful enough to diagnose LOAD.
Since the main characteristic of LOAD is the late age of onset,
we looked for age-effects in the DNA methylation profiles. The risk
of developing the disease doubles every 5 years over age 65 and
may affect up to half the people older than 85. If cumulative
stochastic or environmental epigenetic insults do affect disease
development it is to be expected that the epigenetic distance from
the norm increases progressively with age. This is indeed what we
observed for the 24 LOAD brains. An age-dependent epigenetic
drift was also observable in lymphocytes from patients and controls
(Supporting Fig. S1), however the effect was significantly smaller
compared to the brain tissues. The strongest age-effects were
detected in the NCSTN gene that codes for nicastrin, which
participates in the regulation of c-secretase cleavage of the amyloid
precursor protein. The affected neuronal tissues in the AD brains
may be prone to collect epimutations with time due to their post-
mitotic state. In contrast, it can be hypothesized that cells which
are constantly renewed can repair epimutations much more
efficiently. Indeed, only a minor age-specific epigenetic drift could
be identified for the lymphocytes in our samples, although we
analyzed just a limited number of samples.
Age-dependent methylation changes associated with AD have
been previouslyreported forthe APP gene.Toghietal.,reportedthat
some of the CpG sites within the APP promoter can be partially
methylated in brains of healthy individuals (,26% methylation),
accompanied by a reduction with age (,8%) in methylcytosine
content in these CpG sites [36]. However, in contrast to the previous
study, using a more sensitive technique we could not replicate any
age-specific effects in our brain samples, where APP seemed to be
stably hypomethylated (,20%) throughout old age in healthy
subjects and LOAD cases. The discrepancy may be largely due to
the limited sample size and sensitivity of the older study.
Interestingly, it could be shown that the APP gene can be
monoallelically expressed at certain stages in a subset of individuals
Alzheimer’s Epigenetics
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increasingly affected by epigenetic deregulation, resulting in a higher
susceptibility to an earlier onset of AD [37].
It is known that some DNA methylation patterns can change
with aging progressively in a complex, cell-type specific fashion
[24,38]. Although several reports showed that an overall decrease
in methylcytosine content with aging in many vertebrate tissues is
a common phenomenon (reviewed in [39]), in our brain and
lymphocyte samples we did not observe any significant progressive
change in methylation levels.
Epigenetic theory of LOAD
Many studies demonstrated that epigenetic alterations occur in
higher frequency than genetic mutations and could, thus, be
particularly important in age-related phenotypes [40,41]. The
high frequency of de novo epimutations suggests that epigenetic
alterations accumulate during ageing. Small epimutations in the
critical genes may be tolerated to a certain degree and merely
reflect the range of interindividual variance. However, once a
critical threshold of epigenetic deregulation is reached, the brain
starts to malfunction. In this regard, LOAD may represent merely
an extreme form of normal aging, which would imply that every
human being has a certain predisposition to develop Alzheimer’s.
In our model, the epigenetic effects can accumulate throughout
life, especially from the time-point when the epigenetic machinery
suffers from old age, but also from early embryonal stages or even
trans-generational, influenced by epigenetic events in the parents.
A particularly illustrative example of environmental effects was
reported by Basha et al., which demonstrated that exposure of rats
to lead (Pb) from birth to postnatal day 20 showed a delayed
overexpression of APP and elevation of its amyloidogenic Ab
production in old age [42]. Similarly, it was reported that the
expression of APP and BACE were elevated in aged cynomolgus
monkeys that were exposed to Pb as infants, implicating that
environmental agents may play a role in the pathogenesis of AD
[43]. Support for the idea that LOAD may merely represent an
extreme form of aging or age-dependant epigenetic drift comes
from a system level analysis of transcriptional changes in AD and
normal aging [44]. Strikingly, it was found that specific genes not
only show remarkable parallel expression changes in AD and
aging, but many also cluster into modules within a transcriptional
coexpression network related to synaptic and mitochondrial
function, supporting the notion that LOAD and normal aging
share common pathophysiological processes.
Several additional phenomena exist that support an epigenetic
model of LOAD development (see also Supporting Text S1). For
example, concordance rates of monozygotic (MZ) twins are far
from 100% and were estimated from 21% to 83%. If the major
disease causing factors were genetic, higher concordance rates
would be expected. Furthermore, the onset of AD between MZ
twins who eventually even became concordant often differs more
than 2 decades [23], further supporting the effect of either harmful
or protective environmental or epigenetic factors playing a
significant role in the occurrence of AD.
Another typical sign of epigenetic deregulation is the occurrence
of gender effects; however we observed only minor abnormalities
within the DNMT1 promoter in male LOAD brains. These results
are in agreement with previous data from the human epigenome
project [12], which did not detect any significant methylation
differences between sexes in 873 analyzed genes.
Another typical epigenetic abnormality observed in LOAD
patients is an abnormal one-carbon methylation metabolism,
indicative by elevated plasma homocysteine (Hcy) and low serum
folate concentrations. Both Hcy and folate are critical components
of a series of biosynthetic pathways essential for DNA and histone
methylation reaction. Epidemiological studies have shown that
elevations in plasma Hcy temporally precede the development of
dementia and that there is an inverse linear relation between
plasma Hcy concentrations and cognitive performance in older
persons [26–29]. These observations could indicate that some
epigenomic pathways are disrupted before the main LOAD
phenotypes, such as the forming of amyloid plaques, occur. It was
also reported that S-Adenosymethionine (SAM), which is required
for the methylation of DNA as well as methylation of histones, is
severely decreased in the spinal fluid and brains of AD patients
[45,46]. It is interesting to note that total Hcy levels are not only
increased in AD patients compared to controls, but also
significantly increased in LOAD compared to early-onset AD
(EOAD) [47], indicating that in both AD subtypes two very
different events are taking place, which eventually lead to the same
AD phenotypes.
Another component of the methylation pathways is the
methylenetetrahydrofolate reductase (MTHFR) that catalyzes the
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahy-
drofolate, a co-substrate for homocysteine remethylation to
methionine. An extreme deficiency of MTHFR results in severe
hyperhomocysteinemia and brain abnormalities and may be
associated with a decrease of global DNA methylation level. In
our brain samples the MTHFR promoter displayed a high
interindividual variance in DNA methylation. Some extreme
methylation levels may, in addition to known polymorphisms that
are known to influence Hcy levels, be involved in the observed
elevated Hcy levels in AD patients.
Another, not very well understood phenomenon in AD is the
occurrence of chromatin abnormalities and aberrant histone
regulation. Using the cytosine nucleoside analogue and antileuke-
mic drug 5-azacytidine (5-AzaC) on cultured lymphocytes, it was
shown that AD patients have a significantly increased frequency of
undercondensation of constitutive heterochromatin of chromo-
somes 1, 9 and 16, when compared with control groups [48]. This
study identified an age-dependent 5-AzaC sensitive region on
chromosome 19q13 encompassing the APOE gene, which may
indicate that with increased age, the chance of chromosomal
abnormalities increases. It is likely that the epigenetic patterns in
the cells serve as long-term memory storage [49]. Epigenetic drift
would interfere with this information storage and it could be
expected that some neurons would lose their epigenetic memory,
resulting in mitotic competence and cell cycle reactivation, a
phenomenon that was observed in vulnerable regions of AD
brains, but not control brains [50].
In summary, the data from our study suggest that in addition to
genetic determinants and environmental effects, an important
factor in occurrence of LOAD is epigenetic variability. Epigenetic
drift and interindividual DNA methylation profiles may affect
LOAD predisposition and course of disease. Instead of single
biomarkers, epigenetic drift may be a suitable marker for disease
predisposition. More studies are needed to address this possibility.
Materials and Methods
DNA-Samples
Post-mortem brain tissues derived from the prefrontal cortex of
individuals with diagnosed AD (n=24) and matched controls
(n=10) were provided by the Department of Neuropathology at
the Ludwig-Maximilian University in Munich. The samples
consisted of frozen tissue sections, which were stored at 280uC
prior to nucleic acid extraction. Lymphocyte samples with
diagnosed AD (n=6) and matched controls (n=6) were collected
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matched for geographical location, ethnicity, sex and age and
consisted of cognitively healthy individuals (for details see
Supporting Material & Methods S1).
Bisulfite treatment of genomic DNA
Bisulfite treatment was performed using a standard protocol as
described by Clark and colleagues [51]. Briefly, ,500 ng genomic
DNA was denatured in 0.3 M NaOH for 15 min at 37uC. After
adding freshly prepared 3.5 M sodium metabisulfite (Sigma) and
1 mM Hydroquinone (Sigma) solution, samples were subjected to 4-
hour incubation at 55uC under exclusion of light. The samples were
then purified using Qiagen DNA purification columns (Qiagen).
Recovered samples were desulfonated in 0.3 M NaOH for 15 min
at 37uC and neutralized. DNA was precipitated overnight in ethanol
at 220uC and resuspended in 50 ml buffer EB (Qiagen). Bisulfite
treated DNA was stored at 280uC until needed.
Primer design and MS measurements
A fulllist of primer sequences and annealing temperatures for each
PCR reaction can be found in Supporting Table 1. PCR
amplifications were performed using a standard hot-start PCR
protocol in 20 ml volume reactions containing 2 mlofsodium-bisulfite
treated DNA. All PCR reactions were checked on a 1.0% agarose gel
to ensure successful amplification and specificity before proceeding
with the MALDI. For the MALDI analysis, bisulfite-PCR products
were processed according to the manufacturer’s standard protocol
(Sequenom, USA). Detailed PCR and in vitro transcription
conditions are described in the Supporting Material & Methods S1.
The cleavage reactions (20–25 nl) were robotically dispensed onto
SpectroCHIP silicon chips preloaded with matrix (Sequenom). Mass
spectrawere collected using a MassARRAYHCompact Analyzer and
a Bruker Autoflex mass spectrometer. Spectra were analyzed using
the EpiTYPER (Sequenom) software tool.
Data analysis
Comparison of DNA methylation distances across
individuals. The distribution of the methylation intensities at
a specific site in a group of individuals does not follow a Gaussian
distribution; hence to identify differentially methylated sites
between cases and controls, we used the Wilcox rank sum test
for the null hypothesis of equal distributional locations (medians).
The p-value returned from the test is 2log10 transformed and
serves as the y-coordinate; the difference in the medians input to
the test serves as the x-coordinate. The test was run site by site,
resulting in the ‘volcano’ plot. Top corners of the plot encompass
sites that are significantly different in methylation between the two
groups (either AD vs. control or male vs. female). Adjustment of p-
values for multiple testing was performed by the Bonferroni
method since the number of sites is not large.
Epigenetic distance. The deviation d of the methylation
profile of an affected individual to the group of unaffected controls
is measured by the Euclidean distance,
di ðÞ ~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X 124
j~1
mj i ðÞ {SmTj
   2
v u u t
where mj(i) is the methylation intensity at site j of affected
individual i and ,m.j is the median methylation of the controls at
site j. The larger the d(i), the more different individual i is from the
group of controls. We then calculated the Pearson product-
moment correlation coefficient between the AD patients’
methylation deviates d’s and their ages. The p-value associated
with the correlation coefficient indicates the probability of the
correlation being due to chances alone. For a detailed description
of hierarchical clustering and principal component analysis see
Supporting Material & Methods S1.
Web resources
The DNA methylation data presented herein can be accessed at
our Epigenetics database under this URL: http://www.methylo-
gix.com/genetics/database.shtml.htm
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0002698.s001 (0.05 MB
DOC)
Figure S1 Age-specific epigenetic drift in human lymphocytes.
The epigenetic Euclidean distance of 12 lymphocyte samples
compared to the ‘epigenetic norm’ increases with age (r=0.24; p-
value=0.46), however less increase compared to the LOAD brain
samples.
Found at: doi:10.1371/journal.pone.0002698.s002 (0.30 MB TIF)
Figure S2 Age-specific DNA methylation in brains. Despite a
significant epigenetic drift, represented by demethylation and de
novo methylation of gene promoters with age in individuals with
late-onset AD patients, most genes retained an average methyl-
ation with ongoing age.
Found at: doi:10.1371/journal.pone.0002698.s003 (1.23 MB TIF)
Figure S3 Principal component analysis (PCA) of 34 brain
samples using the five most significant CpG sites. Black circles=-
LOAD brains; orange circles=control brains. A further visuali-
zation of the epigenetic relationship of the brain samples in
relation to the identified top LOAD markers using principle
component analysis (PCA) also demonstrated a clustering and
hence similarity of a substantial part of the LOAD samples. A:
Three dimensional PCA. B: Biplot PCA. Two neighboring points
indicate two similar brains in terms of the five sites. Two
neighboring lines indicate high correlation between the two sites
among the brains. Points along a line indicate brains that vary in
methylation at the site. The roughly even spacing of the five lines
in the resulting biplot indicates that the five selected sites work
synergistically in distinguishing the brains.
Found at: doi:10.1371/journal.pone.0002698.s004 (0.60 MB TIF)
Text S1 Supporting text file
Found at: doi:10.1371/journal.pone.0002698.s005 (0.09 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0002698.s006 (0.08 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0002698.s007 (0.04 MB
DOC)
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